FDA releases information on Exondys 51; Sanofi’s dengue vaccine faces new restrictions; Kellyanne Conway named opioid czar
Alex Azar, previously a senior executive at Eli Lilly, proposed granting Part B the authority to negotiate lower prices.
FDA plans new guidance to bring complex generics to market more quickly; BioMarin sells priority review voucher for $125 million; Takeda expects Zika clinical trial results next year
J&J to hold meeting on maintaining Remicade market share; Acorda ends development of Parkinson’s drug; Darzalex notches positive first-line results
The FDA approves EpiPen competitor Auvi-Q for small children; pharma executives are warm up to Amazon; Purdue approached states about opioid-epidemic settlement
FDA approves Genentech’s hemophilia drug; former Insys CEO pleads not guilty to bribery charges; federal jury rules in favor of Endo in Testim lawsuit
FDA approves AstraZeneca asthma drug; Senate tax reform bill would repeal Obamacare mandate; J&J drops Remicade biosimilar lawsuit
AstraZeneca sales fall on generic competition; Anthem broadens access for Duchenne muscular dystrophy drug; researchers are developing new biopsy techniques